Docetaxel, Gemcitabine and Bevacizumab for Metastatic Breast Cancer

NCT00754351 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Bevacizumab
DRUG: Docetaxel
DRUG: Gemcitabine

Sponsor

University Hospital of Crete